Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 4, 2013 in Colorectal cancer | 0 comments

In a nutshell

The present study evaluated the long-term quality of life (QOL) for patients with peritoneal carcinomatosis (PC) who had cytoreductive surgery (CRS) and HIPEC (hyperthermic perioperative chemotherapy). Main findings: patients who survived the procedure regained their baseline (pre-operative) QOL within 6-12 months after treatment.

Some background

PC is a type of metastatic (stage IV) cancer that has spread from the bowel, ovaries or other abdominal organs to the peritoneum (a sheath lining the cavity of the abdomen and covering the abdominal organs). A treatment option for these patients is CRS (removal of cancerous tissue that cannot be completely excised, along with the peritoneum), followed by HIPEC (after the cancer is removed, the abdominal cavity is washed with a warm solution of chemotherapy). Despite the high risks of this therapy, current data shows that CRS and HIPEC significantly improve survival for patients with PC.

Methods & findings

The study included 90 patients with PC (due to colorectal, appendiceal and other types of cancer) who had CRS and HIPEC between February 2005 and July 2010. Patients’ QOL before the surgery was compared with the QOL 6, 12, 24 and 36 months after the surgery. QOL was evaluated through physical, emotional and social well-being and symptoms like pain, tiredness, sleep disturbances or heavy breathing.

6 months after treatment, patients significantly regained their physical strength and recovery was almost complete after 2 years. Full emotional rehabilitation took in average 1 year. The tiredness, heavy breathing and sleep disturbances continued 6 months after surgery, but improved later on.

The bottom line

To summarize, in this trial, patients with PC who had CRS and HIPEC recovered most QOL constituents within 6-12 months after the procedure.

The fine print

However, results can vary because of different cancer types, patients’ age and other health problems. Due to these arguments, the risks of this treatment should be weighed carefully against its benefit individually.   

Published By :

Annals of Surgical Oncology

Date :

Jan 01, 2013

Original Title :

Quality of Life in Patients after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is It Worth the Risk?

click here to get personalized updates